Pandala N, De Melo Haefeli L, Lang M, Stone EM, Mullins RF, Tucker BA, Han IC (2025) Development of a targeted choroidal injury model for the study of retinal degenerations and therapeutic cell replacement. bioRxiv 2025.07.29.667466. doi: 10.1101/2025.07.29.667466
Objective: To report a new targeted choroidal injury model using saporin conjugates and compare them to models of systemic sodium iodate administration.
Summary: Suprachoroidal administration of Anti-CD38-SAP or Anti-CD105-SAP resulted in severe choroidal vascular injury localized to the injection site, without damage to adjacent choroidal vasculature, progressive injury over time, or development of choroidal neovascularization. By contrast, sodium iodate treated animals had rapid, diffuse choroidal loss which progressed throughout the study time points, with fatal systemic side effects at the highest (75 mg/kg) dose.
Usage: Anti-CD38-SAP (IT-96) or Anti-CD105-SAP (IT-80) were diluted in sterile PBS at a concentration of 0.05 μg/μl. To induce selective choroidal cell injury, 10μl of saporin conjugate solution was delivered via suprachoroidal injection.
Related Products: Anti-CD38-SAP Kit (Cat. #IT-96), Anti-CD105-SAP (Cat. #IT-80)
episode11